Cargando…
High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome
INTRODUCTION: Dyslipidemia frequently occurs in women with polycystic ovary syndrome (PCOS), but it is unclear whether dyslipidemia is due to obesity and insulin resistance (IR) or is inherent to PCOS. To address this, proteomic analysis of proteins important in lipid metabolism, particularly for hi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171110/ https://www.ncbi.nlm.nih.gov/pubmed/37181037 http://dx.doi.org/10.3389/fendo.2023.1117761 |
_version_ | 1785039358150049792 |
---|---|
author | Butler, Alexandra E. Moin, Abu Saleh Md Reiner, Željko Sathyapalan, Thozhukat Jamialahmadi, Tannaz Sahebkar, Amirhossein Atkin, Stephen L. |
author_facet | Butler, Alexandra E. Moin, Abu Saleh Md Reiner, Željko Sathyapalan, Thozhukat Jamialahmadi, Tannaz Sahebkar, Amirhossein Atkin, Stephen L. |
author_sort | Butler, Alexandra E. |
collection | PubMed |
description | INTRODUCTION: Dyslipidemia frequently occurs in women with polycystic ovary syndrome (PCOS), but it is unclear whether dyslipidemia is due to obesity and insulin resistance (IR) or is inherent to PCOS. To address this, proteomic analysis of proteins important in lipid metabolism, particularly for high-density lipoprotein cholesterol (HDL-C), was performed in non-obese, non-insulin resistant PCOS women compared to matched controls. METHODS: Weight and aged-matched non-obese subjects with PCOS (n=24) and without IR were compared with control women (n=24). 19 proteins were measured by Somalogic proteomic analysis: alpha-1-antichymotrypsin, alpha-1-antitrypsin, apolipoproteins A-1, B, D, E, E2, E3, E4, L1, M, clusterin, complement C3, hemopexin, heparin cofactor-II (HCFII), kininogen-1, serum amyloid A-1, amyloid beta A-4 and paraoxonase-1. RESULTS: Women with PCOS had a higher free androgen index (FAI) (p<0.001) and anti-Mullerian hormone (AMH) (p<0.001), but IR and C-reactive protein (CRP), a marker of inflammation, did not differ from controls (p>0.05). The triglyceride:HDL-cholesterol ratio was elevated (p=0.03) in PCOS. Alpha-1-antitrypsin levels were lower (p<0.05) and complement C3 levels were higher (p=0.001) in PCOS. C3 correlated with body mass index (BMI) (r=0.59, p=0.001), IR (r=0.63, p=0.0005) and CRP (r=0.42, p=0.04) in women with PCOS, though no correlations of these parameters with alpha-1-antitrypsin were found. Total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol and levels of the other 17 lipoprotein metabolism-associated proteins did not differ between the two groups (p>0.05). However, in PCOS, alpha-1-antichymotrypsin correlated negatively with BMI (r=-0.40, p<0.04) and HOMA-IR (r=-0.42, p<0.03), apoM correlated positively with CRP (r=0.36, p<0.04) and HCFII correlated negatively with BMI (r=-0.34, p<0.04). CONCLUSION: In PCOS subjects, when obesity, IR and inflammation confounders were absent, alpha-1-antitrypsin was lower and complement C3 was higher than in non-PCOS women, suggesting increased cardiovascular risk; however, subsequent obesity related IR/inflammation likely stimulates other HDL-associated protein abnormalities, thus increasing cardiovascular risk further. |
format | Online Article Text |
id | pubmed-10171110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101711102023-05-11 High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome Butler, Alexandra E. Moin, Abu Saleh Md Reiner, Željko Sathyapalan, Thozhukat Jamialahmadi, Tannaz Sahebkar, Amirhossein Atkin, Stephen L. Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Dyslipidemia frequently occurs in women with polycystic ovary syndrome (PCOS), but it is unclear whether dyslipidemia is due to obesity and insulin resistance (IR) or is inherent to PCOS. To address this, proteomic analysis of proteins important in lipid metabolism, particularly for high-density lipoprotein cholesterol (HDL-C), was performed in non-obese, non-insulin resistant PCOS women compared to matched controls. METHODS: Weight and aged-matched non-obese subjects with PCOS (n=24) and without IR were compared with control women (n=24). 19 proteins were measured by Somalogic proteomic analysis: alpha-1-antichymotrypsin, alpha-1-antitrypsin, apolipoproteins A-1, B, D, E, E2, E3, E4, L1, M, clusterin, complement C3, hemopexin, heparin cofactor-II (HCFII), kininogen-1, serum amyloid A-1, amyloid beta A-4 and paraoxonase-1. RESULTS: Women with PCOS had a higher free androgen index (FAI) (p<0.001) and anti-Mullerian hormone (AMH) (p<0.001), but IR and C-reactive protein (CRP), a marker of inflammation, did not differ from controls (p>0.05). The triglyceride:HDL-cholesterol ratio was elevated (p=0.03) in PCOS. Alpha-1-antitrypsin levels were lower (p<0.05) and complement C3 levels were higher (p=0.001) in PCOS. C3 correlated with body mass index (BMI) (r=0.59, p=0.001), IR (r=0.63, p=0.0005) and CRP (r=0.42, p=0.04) in women with PCOS, though no correlations of these parameters with alpha-1-antitrypsin were found. Total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol and levels of the other 17 lipoprotein metabolism-associated proteins did not differ between the two groups (p>0.05). However, in PCOS, alpha-1-antichymotrypsin correlated negatively with BMI (r=-0.40, p<0.04) and HOMA-IR (r=-0.42, p<0.03), apoM correlated positively with CRP (r=0.36, p<0.04) and HCFII correlated negatively with BMI (r=-0.34, p<0.04). CONCLUSION: In PCOS subjects, when obesity, IR and inflammation confounders were absent, alpha-1-antitrypsin was lower and complement C3 was higher than in non-PCOS women, suggesting increased cardiovascular risk; however, subsequent obesity related IR/inflammation likely stimulates other HDL-associated protein abnormalities, thus increasing cardiovascular risk further. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10171110/ /pubmed/37181037 http://dx.doi.org/10.3389/fendo.2023.1117761 Text en Copyright © 2023 Butler, Moin, Reiner, Sathyapalan, Jamialahmadi, Sahebkar and Atkin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Butler, Alexandra E. Moin, Abu Saleh Md Reiner, Željko Sathyapalan, Thozhukat Jamialahmadi, Tannaz Sahebkar, Amirhossein Atkin, Stephen L. High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title | High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title_full | High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title_fullStr | High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title_full_unstemmed | High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title_short | High density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
title_sort | high density lipoprotein-associated proteins in non-obese women with and without polycystic ovary syndrome |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171110/ https://www.ncbi.nlm.nih.gov/pubmed/37181037 http://dx.doi.org/10.3389/fendo.2023.1117761 |
work_keys_str_mv | AT butleralexandrae highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT moinabusalehmd highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT reinerzeljko highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT sathyapalanthozhukat highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT jamialahmaditannaz highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT sahebkaramirhossein highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome AT atkinstephenl highdensitylipoproteinassociatedproteinsinnonobesewomenwithandwithoutpolycysticovarysyndrome |